September 25, 2007 - The Sorin Group, a European cardiovascular company, announced today that it has received FDA clearance for marketing its MEMO 3D Semirigid Annuloplasty Ring in the U.S., targeting patients receiving mitral valve repair as therapy for mitral valve disease.
Annuloplasty rings are indicated for repair of the mitral valve and are designed to remodel the anatomical shape of the mitral annulus, preventing further dilatation and minimizing the risk of late repair failures.
